Long-Term Cardiovascular Risks of Psychostimulant Drugs for Treatment of Attention-Deficit/Hyperactivity Disorder (ADHD)

By sjmartinez • May 9, 2024

Alexander GC, Moore TJ, Brass EP. Long-Term Cardiovascular Risks of Psychostimulant Drugs for Treatment of Attention-Deficit/Hyperactivity Disorder (ADHD). J Am Coll Cardiol. 2024 May 14;83(19):1883-1885. doi: 10.1016/j.jacc.2024.03.409. PMID: 38719368.

Tags: attention deficit disorder with hyperactivity, central nervous system stimulants, Endocrinology, Harbor UCLA, prescribing indicators, prescribing quality, Publications, quality of care

Closing the Distance: A Qualitative Study to Identify Equitable Innovations for Rural Thyroid Cancer Treatment

Huston-Paterson HH, Mao YV, Hughes EG, Bobanga I, Wu JX, Yeh MW. Closing the Distance: A Qualitative Study to Identify Equitable Innovations for Rural Thyroid[...]

A prognostic molecular signature of hepatic steatosis is spatially heterogeneous and dynamic in human liver

Perry AS, Hadad N, Chatterjee E, Jimenez-Ramos M, Farber-Eger E, Roshani R, Stolze LK, Betti MJ, Zhao S, Huang S, Martens L, Kendall TJ, Thone[...]

Evaluation of dimethandrolone undecanoate in non-human primates as a candidate for long-acting injectable male contraceptive

Bunin DI, Kim K, Parman T, Gahagen J, Zelinski MB, Adevai T, Wang C, Tang L, Iyer L, Endsley A, Blithe DL, Lee MS. Evaluation[...]